Share on StockTwits
 

Albany Molecular Research (NASDAQ:AMRI) major shareholder Stuart M. Cable sold 30,000 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $12.00, for a total value of $360,000.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Separately, analysts at Sterne Agee downgraded shares of Albany Molecular Research from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 3rd. They now have a $12.00 price target on the stock, down previously from $15.00.

Albany Molecular Research (NASDAQ:AMRI) traded up 0.73% on Friday, hitting $12.50. 311,769 shares of the company’s stock traded hands. Albany Molecular Research has a 52 week low of $7.75 and a 52 week high of $14.37. The stock has a 50-day moving average of $10. and a 200-day moving average of $11.77. The company has a market cap of $388.5 million and a price-to-earnings ratio of 37.72.

Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.05. Analysts expect that Albany Molecular Research will post $0.69 EPS for the current fiscal year.

Albany Molecular Research, Inc (NASDAQ:AMRI) provides scientific services, technologies and products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.